Albany, New York (PRWEB) June 25, 2014
The global pain management therapeutics market is expected to witness a decline during the forecast period (2012 to 2018) due to patent expirations of the key blockbuster revenue generating drugs such as Cymbalta (duloxetine) of Eli Lilly & Co. and Lyrica (pregabalin) of Pfizer, Inc. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics.
Browse the full Pain Management Therapeutics Market Report: http://www.transparencymarketresearch.com/pain-management-therapeutics.html.
The various pain management indications studied in this report include neuropathic pain, fibromyalgia, arthritic pain, chronic back pain, migraine, post-operative pain and cancer pain. Market sizes and forecasts for the period 2010 – 2018 have been provided for each of the segments and sub-segments in terms of USD million, considering 2011 as the base year. The % compound annual growth rate (CAGR) for each market segment for the forecast period (2012 to 2018) has been provided along with market size estimations.
For further inquiries, ask here: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1059.
Geographically, the market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The respective market sizes and forecasts have been provided for each of these regions along with the CAGR. The market overview section of the report provides a detailed breakdown of various aspects of market dynamics such as drivers, restraints and opportunities along with market attractiveness analysis and Porter’s five force analysis for the pain management therapeutics market.
The competitive landscape section includes market share analysis of all the leading players in the branded pharmaceuticals market for pain management, in terms of percentage share in the year 2011. Some of the major players profiled in this report include Abbott Laboratories, Inc., AstraZeneca PLC, Eli Lilly & Co., Endo Health Solutions, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc. and Purdue Pharma LP.
The global pain management market is segmented into the following categories:
Pain Management Therapeutics Market, by Therapeutic Class
Request for customization of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1059.
Pain Management Therapeutics Market, by Indication
Pain Management Therapeutics Market, by Geography
90 Sate Street, Suite 700
Albany, NY 12207
USA/Canada Toll Free: 866-552-3453